Jacobson Pharma Corporation Limited provided earning guidance for the year ended 31 March 2023 . The board of directors (the "Directors") of the Company (the "Board") wishes to inform shareholders of the Company (the "Shareholders") and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the year ended 31 March 2023 and the information currently available to the Board, the Group expects to record an increase of not less than 40% in the consolidated profit attributable to equity shareholders of the Company for the year ended 31 March 2023 as compared to that for the year ended 31 March 2022.
The increase was attributable to the gradual easing of pandemic-related restrictive measures in the Mainland China, Hong Kong and Macau, which (a) facilitated the resumption of medical consultation visits in both public and private sectors in Hong Kong, thus boosting the demand for essential drugs and specialty medicines for chronic diseases; and (b) heightened retail spending sentiment and overall sales demand of the Group's products in the branded healthcare segment. This uplift in sales demand, alongside cost savings from operating leverage, coupled with the subsidies from the Hong Kong Government pertinent to the Employment Support Scheme, resulted in a notable increase in profit for the year ended31 March 2023. Thanks to the scalable production capacities and target-oriented product development capabilities, the Group will vigorously pursue the growth strategies and thereby
fortifying its strong market position.